Pyrrolopyrimindine cdk9 kinase inhibitors

A compound having Formula (Ia), or a pharmaceutically acceptable salt thereof,

• wherein
• R1 is selected from the group consisting of phenyl, 5 to 6 membered heteroaryl, 4 to 7 membered heterocycloalkyl and 4 to 7 membered heterocycloalkenyl;
• wherein the R1 phenyl, 5 to 6 membered heteroaryl, 4 to 7 membered heterocycloalkyl and 4 to 7 membered heterocycloalkenyl are optionally substituted with one or more substituents selected from the group consisting of R1A, OR1A, NHSO2R1A, halo, CN, and NHR1A;
• R1A, at each occurrence, is independently selected from the group consisting of C1-C3-haloalkyl, O—C1-C3-haloalkyl, C1-C6-alkyl, C1-C3 alkylene-phenyl, C1-C3 alkylene-(5 to 6 membered heteroaryl), and C1-C3 alkylene-(4 to 7 membered heterocycloalkyl);
• wherein the R1A phenyl, 5 to 6 membered heteroaryl, and 4 to 7 membered heterocycloalkyl rings are optionally substituted with one to three substituents independently selected from the group consisting of CN, C1-C3 alkyl, halo, OH, OR14, NH2, NHR15, NR15R16, C(O)NH2, C(O)NHR15, C(O)NR15R16, SO2NH2, SO2NHR15, SO2NR15R16, C(O)OH, and C(O)OR17;
• R2 is selected from the group consisting of cycloalkyl, cycloalkenyl, heterocycloalkyl and heterocycloalkenyl;
• wherein the R2 cycloalkyl, cycloalkenyl, heterocycloalkyl and heterocycloalkenyl are optionally substituted with one or more R2A;
• R2A, at each occurrence, is independently selected from the group consisting of halo, NHR5, SO2R7, SO2NH2, SO2NHR5, SO2NR5R6, SO2NHC(O)OR8, C(O)R8, C(O)OR8, C(O)OH, C(O)NH2, C(O)NHR5, C(O)NR5R6, C1-C5 alkyl, C2-C5 alkenyl, aryl, 5 to 6 membered heteroaryl, 4 to 7 membered heterocycloalkyl, 4 to 7 membered heterocycloalkenyl, and C3-C7 cycloalkyl;
• wherein the R2A C1-C5 alkyl, C2-C5 alkenyl, aryl, 5 to 6 membered heteroaryl, 4 to 7 membered heterocycloalkyl, and C3-C7 cycloalkyl are optionally substituted with one, two, or three substituents independently selected from the group consisting of R4, OR10, SO2R9, C(O)R10, C(O)R10, NH2, NHR11, NR11R12, NHC(O)R10, NR11C(O)R10, NHS(O)2R9, NR11S(O)2R9, NHC(O)NH2, NHC(O)NHR11, NHC(O)NR11R12, NR11C(O)NHR12, NR11C(O)NR11R13, C(O)NH2, C(O)NHR11, C(O)NR11R12, SO2NH2, SO2NHR11, SO2NR11R12, C(O)OH, OH, CN, and halo;
• R3 is selected from the group consisting of hydrogen, C1-C4 alkyl, NO2, CN, F, Cl, Br and I;
• R4, at each occurrence, is independently selected from the group consisting of C1-C5 alkyl, C1-C5 alkenyl, aryl, 5 to 6 membered heteroaryl, 4 to 7 membered heterocycloalkyl, and C3-C7 cycloalkyl;
• wherein the R4C1-C5 alkyl and C1-C5 alkenyl are optionally substituted with one or more substituents selected from the group consisting of halo, C1-C3-haloalkyl, C(O)OH, CN, and NH2;
• wherein the R4 aryl, 5 to 6 membered heteroaryl, 4 to 7 membered heterocycloalkyl, and C3-C7 cycloalkyl are optionally substituted with one or more substituents selected from the group consisting of halo, C1-C3-haloalkyl, C(O)OH, CN, NH2, NHSO2R17;
• NHC(O)R17, C(O)R17, C(O)OR17, and NHC(O)OR17;
• R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, and R17, at each occurrence, are independently selected from the group consisting of C1-C6 alkyl, C1-C3-haloalkyl, C2-C5 alkenyl, aryl, 5 to 6 membered heteroaryl, 4 to 7 membered heterocycloalkyl, and C3-C7 cycloalkyl;
• wherein the R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, and R17C1-C6 alkyl, C1-C3-haloalkyl, C2-C5 alkenyl, aryl, 5 to 6 membered heteroaryl, 4 to 7 membered heterocycloalkyl, and C3-C7 cycloalkyl are optionally substituted with one or more substituents selected from the group consisting of C1-C6 alkyl, C3-C7 cycloalkyl, (O), OH, C(O)OR18, OR18, and C(O)OH;
• and
• R18, at each occurrence, is C1-C6 alkyl.